---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040581"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:38:48.871410+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma Q2 2023: cash $112M, R&D $9.8M; Phase 3 EFZO-FIT enrolling globally

## Summary
- Cash and investments $112.0M as of June 30, 2023; company expects cash runway into 2026.
- R&D expenses $9.8M, G&A $3.7M in Q2 2023.
- Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrolling up to 264 subjects globally.
- Phase 2 EFZO-CONNECT study in SSc-ILD expected to start Q3 2023, enrolling 25 patients.
- Received European Commission orphan drug designation for efzofitimod in systemic sclerosis.

## SEC filing metadata
- accession: 0000950170-23-040581
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017023040581/0000950170-23-040581-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017023040581/life-20230809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040581
- JSON: https://secwatch.observer/filing/0000950170-23-040581.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040581.txt

## Key facts
- Earnings Releases
  aTYR PHARMA INC reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000095017023040581/0000950170-23-040581-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.